Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
less,26579409,plasma protein binding,The plasma protein binding of DRDE-07 was found to be less than 25% at all concentrations studied.,"Preclinical investigation of the pharmacokinetics, metabolism, and protein and red blood cell binding of DRDE-07: a prophylactic agent against sulphur mustard. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579409/),%,25,3600,DB01143,Amifostine
,12576438,MTD,The MTD for irinotecan administered in combination with cisplatin (30 mg/m(2)) was 50 mg/m(2).,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),[mg] / [m],50,7517,DB01143,Amifostine
,12576438,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for free cisplatin and WR-1065 were 4.5 +/- 1.6 micro M and approximately 89 +/- 10 micro M, respectively.",Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),μM,4.5,7518,DB01143,Amifostine
,12576438,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for free cisplatin and WR-1065 were 4.5 +/- 1.6 micro M and approximately 89 +/- 10 micro M, respectively.",Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),μM,89,7519,DB01143,Amifostine
,12576438,half-life (t(1/2)),The half-life (t(1/2)) for free plasma cisplatin was 25.4 +/- 5.4 min.,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),min,25.4,7520,DB01143,Amifostine
,12576438,initial t(1/2),The initial t(1/2) for plasma WR-1065 was approximately 7 min and terminal t(1/2) approximately 24 min.,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),min,7,7521,DB01143,Amifostine
,12576438,terminal t(1/2),The initial t(1/2) for plasma WR-1065 was approximately 7 min and terminal t(1/2) approximately 24 min.,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),min,24,7522,DB01143,Amifostine
,3019967,minimum detectable limit,"Following i.v. administration of ethiofos (120-150 mg per kg body weight) to monkeys, plasma concentrations of unchanged drug ranged from 477 micrograms/mL (2.23 mM) down to the minimum detectable limit of the analytical procedure (0.05 micrograms/mL, 0.23 microM) 2-3 hours postinfusion.",A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3019967/),[μg] / [ml],0.05,53060,DB01143,Amifostine
,3019967,minimum detectable limit,"Following i.v. administration of ethiofos (120-150 mg per kg body weight) to monkeys, plasma concentrations of unchanged drug ranged from 477 micrograms/mL (2.23 mM) down to the minimum detectable limit of the analytical procedure (0.05 micrograms/mL, 0.23 microM) 2-3 hours postinfusion.",A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3019967/),μM,0.23,53061,DB01143,Amifostine
,3019967,Clearances,Clearances averaged 43.5 +/- 13.4 (SD) mL min-1 kg-1 and half-lives observed in the 20-60 minute postinfusion period were 8-15 min.,A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3019967/),[ml] / [kg·min],43.5,53062,DB01143,Amifostine
,3019967,half-lives,Clearances averaged 43.5 +/- 13.4 (SD) mL min-1 kg-1 and half-lives observed in the 20-60 minute postinfusion period were 8-15 min.,A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3019967/),min,8-15,53063,DB01143,Amifostine
,8976819,alpha half-life (T1/2 alpha),Amifostine (Ethyol) administered to cancer patients is rapidly cleared from plasma by a biphasic decay with an alpha half-life (T1/2 alpha) of 0.88 min and a T1/2 beta of 8.8 min.,Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8976819/),min,0.88,54090,DB01143,Amifostine
,8976819,T1/2 beta,Amifostine (Ethyol) administered to cancer patients is rapidly cleared from plasma by a biphasic decay with an alpha half-life (T1/2 alpha) of 0.88 min and a T1/2 beta of 8.8 min.,Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8976819/),min,8.8,54091,DB01143,Amifostine
,8976819,area under the plasma concentration-time curve,"When carboplatin was administered as a 15-min i.v. infusion of 400 mg/m2 and amifostine as a 15-min i.v. infusion of 740 mg/m2 just before and 2 and 4 h after carboplatin, the area under the plasma concentration-time curve for ultrafilterable platinum increased from 253 +/- 45 microM.h (n = 6) for carboplatin alone to 305 +/- 63 microM.h (n = 11) for carboplatin+three doses of amifostine.",Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8976819/),h·μM,253,54092,DB01143,Amifostine
,8976819,area under the plasma concentration-time curve,"When carboplatin was administered as a 15-min i.v. infusion of 400 mg/m2 and amifostine as a 15-min i.v. infusion of 740 mg/m2 just before and 2 and 4 h after carboplatin, the area under the plasma concentration-time curve for ultrafilterable platinum increased from 253 +/- 45 microM.h (n = 6) for carboplatin alone to 305 +/- 63 microM.h (n = 11) for carboplatin+three doses of amifostine.",Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8976819/),h·μM,305,54093,DB01143,Amifostine
,11917293,mucositis score,The average mucositis score for the untreated animals was 3.5.,Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11917293/),,3.5,74108,DB01143,Amifostine
,9815738,final half-life,"Compared with a control group of patients who received carboplatin alone, the patients receiving the combination had a longer final half-life of ultrafilterable platinum species [5.0 h versus 3.5 h in patients with a normal creatinine clearance (Clcr > 80 ml/min); 5.6 h versus 4.2 h in those with an impaired renal function (50 < Clcr < 80 ml/min)].",Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815738/),h,5.0,82951,DB01143,Amifostine
,9815738,final half-life,"Compared with a control group of patients who received carboplatin alone, the patients receiving the combination had a longer final half-life of ultrafilterable platinum species [5.0 h versus 3.5 h in patients with a normal creatinine clearance (Clcr > 80 ml/min); 5.6 h versus 4.2 h in those with an impaired renal function (50 < Clcr < 80 ml/min)].",Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815738/),h,3.5,82952,DB01143,Amifostine
,9815738,final half-life,"Compared with a control group of patients who received carboplatin alone, the patients receiving the combination had a longer final half-life of ultrafilterable platinum species [5.0 h versus 3.5 h in patients with a normal creatinine clearance (Clcr > 80 ml/min); 5.6 h versus 4.2 h in those with an impaired renal function (50 < Clcr < 80 ml/min)].",Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815738/),h,5.6,82953,DB01143,Amifostine
,9815738,final half-life,"Compared with a control group of patients who received carboplatin alone, the patients receiving the combination had a longer final half-life of ultrafilterable platinum species [5.0 h versus 3.5 h in patients with a normal creatinine clearance (Clcr > 80 ml/min); 5.6 h versus 4.2 h in those with an impaired renal function (50 < Clcr < 80 ml/min)].",Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815738/),h,4.2,82954,DB01143,Amifostine
,9815738,area under the concentration-time curves,The impact of these changes on the area under the concentration-time curves of the ultrafilterable platinum species was hardly noticeable in patients with a normal renal function but led to a significant increase in patients with an impaired renal function (395 +/- 59 micromol/l.h versus 280 +/- 62 micromol/l.h in patients receiving carboplatin alone).,Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815738/),[μM] / [h·l],395,82955,DB01143,Amifostine
,9815738,area under the concentration-time curves,The impact of these changes on the area under the concentration-time curves of the ultrafilterable platinum species was hardly noticeable in patients with a normal renal function but led to a significant increase in patients with an impaired renal function (395 +/- 59 micromol/l.h versus 280 +/- 62 micromol/l.h in patients receiving carboplatin alone).,Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815738/),[μM] / [h·l],280,82956,DB01143,Amifostine
,10550571,rapid,"(1) WR-1065 is rapidly formed from WR-2721 and equilibrates between plasma and blood cells; (2) WR-1065 decays in plasma and blood cells with similar rapid initial half-lives of approximately 16 min; (3) WR-2721 treatment increases cysteine in plasma and blood cells, an effect similar to that of mesna; (4) WR-2721 treatment appears to increase glutathione levels in blood cells; (5) Mesna does not have a substantial effect on the fate of WR-2721 in patients.","WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550571/),min,16,83978,DB01143,Amifostine
,10550571,initial half-lives,"(1) WR-1065 is rapidly formed from WR-2721 and equilibrates between plasma and blood cells; (2) WR-1065 decays in plasma and blood cells with similar rapid initial half-lives of approximately 16 min; (3) WR-2721 treatment increases cysteine in plasma and blood cells, an effect similar to that of mesna; (4) WR-2721 treatment appears to increase glutathione levels in blood cells; (5) Mesna does not have a substantial effect on the fate of WR-2721 in patients.","WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550571/),min,16,83979,DB01143,Amifostine
,9516919,t1/2,"An increase in the final half-life of ultrafilterable platinum was observed after treatment with cisplatin and amifostine (t1/2, 0.77 +/- 0.10 h; n = 8), compared to cisplatin alone (t1/2, 0.57 +/- 0.15 h; n = 8).",Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516919/),h,0.77,90338,DB01143,Amifostine
,9516919,t1/2,"An increase in the final half-life of ultrafilterable platinum was observed after treatment with cisplatin and amifostine (t1/2, 0.77 +/- 0.10 h; n = 8), compared to cisplatin alone (t1/2, 0.57 +/- 0.15 h; n = 8).",Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516919/),h,0.57,90339,DB01143,Amifostine
,8995515,final half-life,"The disulfides, which were rapidly formed from WR 1065, were cleared much more slowly (final half-life 13.6 h).",Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995515/),h,13.6,90578,DB01143,Amifostine
,22440042,Peak concentrations,Peak concentrations of WR-1065 were 25 μM with an elimination half-life of 1.5 h; these levels are consistent with radioprotective effects of amifostine in patients.,A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22440042/),μM,25,100184,DB01143,Amifostine
,22440042,elimination half-life,Peak concentrations of WR-1065 were 25 μM with an elimination half-life of 1.5 h; these levels are consistent with radioprotective effects of amifostine in patients.,A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22440042/),h,1.5,100185,DB01143,Amifostine
,9166935,AUC (area under the curve),"A single dose of amifostine increased the AUC (area under the curve) values of total platinum in plasma ultrafiltrate (30.1 vs 18.2 microM x h), liver (307.7 vs 236.4 nmol g(-1) x h), kidney (500.8 vs 368.3 nmol g(-1) x h) and OVCAR-3 tumour tissue (184.0 vs 146.8 nmol g(-1) x h).",Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9166935/),h·μM,30.1,101974,DB01143,Amifostine
,9166935,AUC (area under the curve),"A single dose of amifostine increased the AUC (area under the curve) values of total platinum in plasma ultrafiltrate (30.1 vs 18.2 microM x h), liver (307.7 vs 236.4 nmol g(-1) x h), kidney (500.8 vs 368.3 nmol g(-1) x h) and OVCAR-3 tumour tissue (184.0 vs 146.8 nmol g(-1) x h).",Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9166935/),h·μM,18.2,101975,DB01143,Amifostine
,9166935,AUC (area under the curve),"A single dose of amifostine increased the AUC (area under the curve) values of total platinum in plasma ultrafiltrate (30.1 vs 18.2 microM x h), liver (307.7 vs 236.4 nmol g(-1) x h), kidney (500.8 vs 368.3 nmol g(-1) x h) and OVCAR-3 tumour tissue (184.0 vs 146.8 nmol g(-1) x h).",Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9166935/),[h·nM] / [g],307.7,101976,DB01143,Amifostine
,9166935,AUC (area under the curve),"A single dose of amifostine increased the AUC (area under the curve) values of total platinum in plasma ultrafiltrate (30.1 vs 18.2 microM x h), liver (307.7 vs 236.4 nmol g(-1) x h), kidney (500.8 vs 368.3 nmol g(-1) x h) and OVCAR-3 tumour tissue (184.0 vs 146.8 nmol g(-1) x h).",Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9166935/),[h·nM] / [g],236.4,101977,DB01143,Amifostine
,9166935,AUC (area under the curve),"A single dose of amifostine increased the AUC (area under the curve) values of total platinum in plasma ultrafiltrate (30.1 vs 18.2 microM x h), liver (307.7 vs 236.4 nmol g(-1) x h), kidney (500.8 vs 368.3 nmol g(-1) x h) and OVCAR-3 tumour tissue (184.0 vs 146.8 nmol g(-1) x h).",Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9166935/),[h·nM] / [g],500.8,101978,DB01143,Amifostine
,9166935,AUC (area under the curve),"A single dose of amifostine increased the AUC (area under the curve) values of total platinum in plasma ultrafiltrate (30.1 vs 18.2 microM x h), liver (307.7 vs 236.4 nmol g(-1) x h), kidney (500.8 vs 368.3 nmol g(-1) x h) and OVCAR-3 tumour tissue (184.0 vs 146.8 nmol g(-1) x h).",Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9166935/),[h·nM] / [g],368.3,101979,DB01143,Amifostine
,9166935,AUC (area under the curve),"A single dose of amifostine increased the AUC (area under the curve) values of total platinum in plasma ultrafiltrate (30.1 vs 18.2 microM x h), liver (307.7 vs 236.4 nmol g(-1) x h), kidney (500.8 vs 368.3 nmol g(-1) x h) and OVCAR-3 tumour tissue (184.0 vs 146.8 nmol g(-1) x h).",Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9166935/),[h·nM] / [g],184.0,101980,DB01143,Amifostine
,9166935,AUC (area under the curve),"A single dose of amifostine increased the AUC (area under the curve) values of total platinum in plasma ultrafiltrate (30.1 vs 18.2 microM x h), liver (307.7 vs 236.4 nmol g(-1) x h), kidney (500.8 vs 368.3 nmol g(-1) x h) and OVCAR-3 tumour tissue (184.0 vs 146.8 nmol g(-1) x h).",Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9166935/),[h·nM] / [g],146.8,101981,DB01143,Amifostine
,12012141,area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)),The inter-individual variability was pronounced and the area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine.,No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],182,105342,DB01143,Amifostine
,12012141,area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)),The inter-individual variability was pronounced and the area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine.,No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],725,105343,DB01143,Amifostine
,12012141,area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)),The inter-individual variability was pronounced and the area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine.,No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],188,105344,DB01143,Amifostine
,12012141,area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)),The inter-individual variability was pronounced and the area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine.,No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],574,105345,DB01143,Amifostine
,12012141,AUC(0-infinity),"The geometric mean of AUC(0-infinity) values were 326 nmol/l h and 297 nmol/l h, respectively ( P=0.41).",No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],326,105346,DB01143,Amifostine
,12012141,AUC(0-infinity),"The geometric mean of AUC(0-infinity) values were 326 nmol/l h and 297 nmol/l h, respectively ( P=0.41).",No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],297,105347,DB01143,Amifostine
,6090354,total chromatography time,The assay uses 150 microL of plasma and requires a total chromatography time of about 50 minutes.,An improved HPLC assay for S-2-(3-aminopropylamino)ethyl phosphorothioate (WR-2721) in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6090354/),min,50,118304,DB01143,Amifostine
,9337685,final half-life,A biphasic decrease with a final half-life of 0.8 h was observed.,Pharmacokinetics of amifostine and its metabolites in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337685/),h,0.8,119386,DB01143,Amifostine
,9337685,final half-life,The active metabolite WR 1065 was cleared from the plasma with a final half-life of 7.3 +/- 3.6 h.,Pharmacokinetics of amifostine and its metabolites in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337685/),h,7.3,119387,DB01143,Amifostine
,9337685,final half-life,The disulphides were cleared with a final half-life of 8.4-13.4 h and were detectable for at least 24 h after treatment.,Pharmacokinetics of amifostine and its metabolites in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337685/),h,8.4-13.4,119388,DB01143,Amifostine
,9337685,"C1,max","For WR 1065 a trend towards an increase in the peak levels was observed [C1,max: 47.5 +/- 11.9 microM, C2,max: 79.0 +/- 13.2 microM, C3,max: 84.8 +/- 15.1 microM, (n = 6)], whereas a trend towards a small decrease was observed for the peak levels of the disulphides [C1,max: 184.2 +/- 12.6 microM, C2,max: 175.0 +/- 23.7 microM, C3,max: 166.0 +/- 17.2 microM, (n = 6)].",Pharmacokinetics of amifostine and its metabolites in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337685/),μM,47.5,119389,DB01143,Amifostine
,9337685,"C2,max","For WR 1065 a trend towards an increase in the peak levels was observed [C1,max: 47.5 +/- 11.9 microM, C2,max: 79.0 +/- 13.2 microM, C3,max: 84.8 +/- 15.1 microM, (n = 6)], whereas a trend towards a small decrease was observed for the peak levels of the disulphides [C1,max: 184.2 +/- 12.6 microM, C2,max: 175.0 +/- 23.7 microM, C3,max: 166.0 +/- 17.2 microM, (n = 6)].",Pharmacokinetics of amifostine and its metabolites in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337685/),μM,79.0,119390,DB01143,Amifostine
,9337685,"C3,max","For WR 1065 a trend towards an increase in the peak levels was observed [C1,max: 47.5 +/- 11.9 microM, C2,max: 79.0 +/- 13.2 microM, C3,max: 84.8 +/- 15.1 microM, (n = 6)], whereas a trend towards a small decrease was observed for the peak levels of the disulphides [C1,max: 184.2 +/- 12.6 microM, C2,max: 175.0 +/- 23.7 microM, C3,max: 166.0 +/- 17.2 microM, (n = 6)].",Pharmacokinetics of amifostine and its metabolites in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337685/),μM,84.8,119391,DB01143,Amifostine
,9337685,"C1,max","For WR 1065 a trend towards an increase in the peak levels was observed [C1,max: 47.5 +/- 11.9 microM, C2,max: 79.0 +/- 13.2 microM, C3,max: 84.8 +/- 15.1 microM, (n = 6)], whereas a trend towards a small decrease was observed for the peak levels of the disulphides [C1,max: 184.2 +/- 12.6 microM, C2,max: 175.0 +/- 23.7 microM, C3,max: 166.0 +/- 17.2 microM, (n = 6)].",Pharmacokinetics of amifostine and its metabolites in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337685/),μM,184.2,119392,DB01143,Amifostine
,9337685,"C2,max","For WR 1065 a trend towards an increase in the peak levels was observed [C1,max: 47.5 +/- 11.9 microM, C2,max: 79.0 +/- 13.2 microM, C3,max: 84.8 +/- 15.1 microM, (n = 6)], whereas a trend towards a small decrease was observed for the peak levels of the disulphides [C1,max: 184.2 +/- 12.6 microM, C2,max: 175.0 +/- 23.7 microM, C3,max: 166.0 +/- 17.2 microM, (n = 6)].",Pharmacokinetics of amifostine and its metabolites in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337685/),μM,175.0,119393,DB01143,Amifostine
,9337685,"C3,max","For WR 1065 a trend towards an increase in the peak levels was observed [C1,max: 47.5 +/- 11.9 microM, C2,max: 79.0 +/- 13.2 microM, C3,max: 84.8 +/- 15.1 microM, (n = 6)], whereas a trend towards a small decrease was observed for the peak levels of the disulphides [C1,max: 184.2 +/- 12.6 microM, C2,max: 175.0 +/- 23.7 microM, C3,max: 166.0 +/- 17.2 microM, (n = 6)].",Pharmacokinetics of amifostine and its metabolites in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337685/),μM,166.0,119394,DB01143,Amifostine
,20103669,clearance,"The population-predicted values for amifostine clearance, volume, and apparent WR1065 clearance from the plasma data were 107 L/h/m(2), 5.53 L/m(2), and 30.6 L/h/m(2).",Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20103669/),[h·l] / [m(2],107,129845,DB01143,Amifostine
,20103669,volume,"The population-predicted values for amifostine clearance, volume, and apparent WR1065 clearance from the plasma data were 107 L/h/m(2), 5.53 L/m(2), and 30.6 L/h/m(2).",Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20103669/),[l] / [m(2],5.53,129846,DB01143,Amifostine
,20103669,apparent WR1065 clearance,"The population-predicted values for amifostine clearance, volume, and apparent WR1065 clearance from the plasma data were 107 L/h/m(2), 5.53 L/m(2), and 30.6 L/h/m(2).",Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20103669/),[h·l] / [m(2],30.6,129847,DB01143,Amifostine
,20103669,clearance,"The population-predicted values for amifostine clearance, volume, and apparent WR1065 clearance from whole blood data were 136 L/h/m(2), 7.23 L/m(2), and 12.5 L/h/m(2).",Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20103669/),[h·l] / [m(2],136,129848,DB01143,Amifostine
,20103669,volume,"The population-predicted values for amifostine clearance, volume, and apparent WR1065 clearance from whole blood data were 136 L/h/m(2), 7.23 L/m(2), and 12.5 L/h/m(2).",Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20103669/),[l] / [m(2],7.23,129849,DB01143,Amifostine
,20103669,apparent WR1065 clearance,"The population-predicted values for amifostine clearance, volume, and apparent WR1065 clearance from whole blood data were 136 L/h/m(2), 7.23 L/m(2), and 12.5 L/h/m(2).",Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20103669/),[h·l] / [m(2],12.5,129850,DB01143,Amifostine
,9893625,AUC,"76 patients were treated with paclitaxel over three hours followed by a 30 min carboplatin infusion, dosed by the Calvert formula to a target AUC of 4.0 or 4.5 mg/min/ml-1.",The clinical development of paclitaxel and the paclitaxel/carboplatin combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893625/),[mg] / [min·ml],4.0,135154,DB01143,Amifostine
,9893625,AUC,"76 patients were treated with paclitaxel over three hours followed by a 30 min carboplatin infusion, dosed by the Calvert formula to a target AUC of 4.0 or 4.5 mg/min/ml-1.",The clinical development of paclitaxel and the paclitaxel/carboplatin combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893625/),[mg] / [min·ml],4.5,135155,DB01143,Amifostine
,11268469,tmax,"In both treatment schedules the steady state of PACLI occurred after 3 hours, the tmax of metabolites between 3 and 4 hours.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),h,3 and 4,136130,DB01143,Amifostine
,11268469,steady-state concentration,The mean steady-state concentration was cmax = 5432 +/- 1238 ng/ml in the control group and cmax = 5140 +/- 2407 ng/ml in the AMI group.,Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],5432,136131,DB01143,Amifostine
,11268469,cmax,The mean steady-state concentration was cmax = 5432 +/- 1238 ng/ml in the control group and cmax = 5140 +/- 2407 ng/ml in the AMI group.,Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],5432,136132,DB01143,Amifostine
,11268469,cmax,The mean steady-state concentration was cmax = 5432 +/- 1238 ng/ml in the control group and cmax = 5140 +/- 2407 ng/ml in the AMI group.,Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],5140,136133,DB01143,Amifostine
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],413,136134,DB01143,Amifostine
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],432,136135,DB01143,Amifostine
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],99,136136,DB01143,Amifostine
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],123,136137,DB01143,Amifostine
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],43,136138,DB01143,Amifostine
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],75,136139,DB01143,Amifostine
,29556791,systemic bioavailability,Direct jejunal AMF administration incurred a systemic bioavailability of 61.5%.,Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556791/),%,61.5,145149,DB01143,Amifostine
,29556791,peak exposure,"Subcutaneously administrated AMF yielded higher systemic levels, a more rapid peak exposure (0.438 vs. 0.875 h), and greater total systemic exposure of WR-1065 (116,756 vs. 16,874 ng*hr/ml) compared to orally administered AMF.",Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556791/),h,0.438,145150,DB01143,Amifostine
,29556791,peak exposure,"Subcutaneously administrated AMF yielded higher systemic levels, a more rapid peak exposure (0.438 vs. 0.875 h), and greater total systemic exposure of WR-1065 (116,756 vs. 16,874 ng*hr/ml) compared to orally administered AMF.",Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556791/),h,0.875,145151,DB01143,Amifostine
,29556791,total systemic exposure,"Subcutaneously administrated AMF yielded higher systemic levels, a more rapid peak exposure (0.438 vs. 0.875 h), and greater total systemic exposure of WR-1065 (116,756 vs. 16,874 ng*hr/ml) compared to orally administered AMF.",Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556791/),[h·ng] / [ml],"116,756",145152,DB01143,Amifostine
,29556791,total systemic exposure,"Subcutaneously administrated AMF yielded higher systemic levels, a more rapid peak exposure (0.438 vs. 0.875 h), and greater total systemic exposure of WR-1065 (116,756 vs. 16,874 ng*hr/ml) compared to orally administered AMF.",Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556791/),[h·ng] / [ml],"16,874",145153,DB01143,Amifostine
,2988391,distribution half-life,"Using high-pressure liquid chromatography with electrochemical detection, plasma pharmacokinetic studies showed that WR-2721's distribution half-life is 0.55 minutes.","Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2988391/),min,0.55,163078,DB01143,Amifostine
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,345,165679,DB01143,Amifostine
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,318,165680,DB01143,Amifostine
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,330,165681,DB01143,Amifostine
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,340,165682,DB01143,Amifostine
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,470,165683,DB01143,Amifostine
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),,200,165684,DB01143,Amifostine
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),,680,165685,DB01143,Amifostine
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),,545,165686,DB01143,Amifostine
,11801544,peak concentration (C(peak),"Mean clearances (liter/h/m(2)) and peak concentration (C(peak); ng/ml) were 29.9 at cycle 1 versus 32.8 at cycle 2 (not significant) and 2849.9 at cycle 1 versus 2542.5 at cycle 2 (not significant), respectively.",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),[ng] / [ml],29.9,165687,DB01143,Amifostine
,11801544,peak concentration (C(peak),"Mean clearances (liter/h/m(2)) and peak concentration (C(peak); ng/ml) were 29.9 at cycle 1 versus 32.8 at cycle 2 (not significant) and 2849.9 at cycle 1 versus 2542.5 at cycle 2 (not significant), respectively.",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),[ng] / [ml],32.8,165688,DB01143,Amifostine
,11801544,peak concentration (C(peak),"Mean clearances (liter/h/m(2)) and peak concentration (C(peak); ng/ml) were 29.9 at cycle 1 versus 32.8 at cycle 2 (not significant) and 2849.9 at cycle 1 versus 2542.5 at cycle 2 (not significant), respectively.",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),[ng] / [ml],2849.9,165689,DB01143,Amifostine
,11801544,peak concentration (C(peak),"Mean clearances (liter/h/m(2)) and peak concentration (C(peak); ng/ml) were 29.9 at cycle 1 versus 32.8 at cycle 2 (not significant) and 2849.9 at cycle 1 versus 2542.5 at cycle 2 (not significant), respectively.",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),[ng] / [ml],2542.5,165690,DB01143,Amifostine
,15380593,clearance rate,The mean clearance rate of (99m)Tc-DTPA in control subjects was 140 +/- 21 min.,The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by (99m)Tc-DTPA transalveolar clearances. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380593/),min,140,167459,DB01143,Amifostine
,15380593,t((1/2)),"The highest t((1/2)) value was noted in the RAD group (603 +/- 105 min, p = 0.001).",The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by (99m)Tc-DTPA transalveolar clearances. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380593/),min,603,167460,DB01143,Amifostine
,15380593,lung clearance rates,"There were no significant differences between the (99m)Tc-DTPA lung clearance rates of the CONT, RAD+AMF (238 +/- 24 min), and AMF groups (227 +/- 54 min).",The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by (99m)Tc-DTPA transalveolar clearances. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380593/),min,238,167461,DB01143,Amifostine
,15380593,lung clearance rates,"There were no significant differences between the (99m)Tc-DTPA lung clearance rates of the CONT, RAD+AMF (238 +/- 24 min), and AMF groups (227 +/- 54 min).",The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by (99m)Tc-DTPA transalveolar clearances. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380593/),min,227,167462,DB01143,Amifostine
,15380593,penetration index,"The mean penetration index values of CONT, RAD, AMF, and RAD+AMF are 63% +/- 1.6%, 63% +/- 2.5%, 60% +/- 2.9%, and 63% +/- 2%, respectively.",The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by (99m)Tc-DTPA transalveolar clearances. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380593/),%,63,167463,DB01143,Amifostine
,15380593,penetration index,"The mean penetration index values of CONT, RAD, AMF, and RAD+AMF are 63% +/- 1.6%, 63% +/- 2.5%, 60% +/- 2.9%, and 63% +/- 2%, respectively.",The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by (99m)Tc-DTPA transalveolar clearances. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380593/),%,63,167464,DB01143,Amifostine
,15380593,penetration index,"The mean penetration index values of CONT, RAD, AMF, and RAD+AMF are 63% +/- 1.6%, 63% +/- 2.5%, 60% +/- 2.9%, and 63% +/- 2%, respectively.",The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by (99m)Tc-DTPA transalveolar clearances. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380593/),%,60,167465,DB01143,Amifostine
,15380593,penetration index,"The mean penetration index values of CONT, RAD, AMF, and RAD+AMF are 63% +/- 1.6%, 63% +/- 2.5%, 60% +/- 2.9%, and 63% +/- 2%, respectively.",The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by (99m)Tc-DTPA transalveolar clearances. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380593/),%,63,167466,DB01143,Amifostine
,9640232,area under the curve (AUC),"A significant increase in the area under the curve (AUC) of the total platinum concentration in mice treated with amifostine was only observed in the kidney (from 355 to 398 nmol h/g), whereas in the other tissues and plasma no significant changes were measured.",Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640232/),[h·nM] / [g],355,171397,DB01143,Amifostine
,9640232,area under the curve (AUC),"A significant increase in the area under the curve (AUC) of the total platinum concentration in mice treated with amifostine was only observed in the kidney (from 355 to 398 nmol h/g), whereas in the other tissues and plasma no significant changes were measured.",Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640232/),[h·nM] / [g],398,171398,DB01143,Amifostine
,9640232,AUC,"The decrease was only significant in the liver (282-240 fmol h/microgram DNA), whereas in tumour tissue a slight increase in the AUC of the cisplatin-DNA adducts could be detected (91.3-110.1 fmol h/microgram DNA).",Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640232/),[fmol·h] / [dna·μg],91.3-110.1,171399,DB01143,Amifostine
,2568913,Urinary excretion,"Urinary excretion of radioactivity following iv and intraduodenal administration of [14C]ethiofos was 78.9 +/- 14.0% and 43.8 +/- 12.4%, respectively, whereas 1.9 +/- 0.5% and 9.7 +/- 6.3% was excreted in feces.",Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568913/),%,78.9,185421,DB01143,Amifostine
,2568913,Urinary excretion,"Urinary excretion of radioactivity following iv and intraduodenal administration of [14C]ethiofos was 78.9 +/- 14.0% and 43.8 +/- 12.4%, respectively, whereas 1.9 +/- 0.5% and 9.7 +/- 6.3% was excreted in feces.",Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568913/),%,43.8,185422,DB01143,Amifostine
,2568913,Urinary excretion,"Urinary excretion of radioactivity following iv and intraduodenal administration of [14C]ethiofos was 78.9 +/- 14.0% and 43.8 +/- 12.4%, respectively, whereas 1.9 +/- 0.5% and 9.7 +/- 6.3% was excreted in feces.",Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568913/),%,1.9,185423,DB01143,Amifostine
,2568913,Urinary excretion,"Urinary excretion of radioactivity following iv and intraduodenal administration of [14C]ethiofos was 78.9 +/- 14.0% and 43.8 +/- 12.4%, respectively, whereas 1.9 +/- 0.5% and 9.7 +/- 6.3% was excreted in feces.",Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568913/),%,9.7,185424,DB01143,Amifostine
,2537989,clearance,Ethiofos clearance (10.6 +/- 3.3 ml h-1) was only a small fraction (1.2 +/- 0.03%) of the perfusate flow rate.,The disposition of ethiofos (WR-2721) in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2537989/),[ml] / [h],10.6,189565,DB01143,Amifostine
,2537989,elimination half-life,The elimination half-life was calculated at 7.1 +/- 1.9 h.,The disposition of ethiofos (WR-2721) in the isolated perfused rat liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2537989/),h,7.1,189566,DB01143,Amifostine
,2537989,"area under curve, AUC0-4 h","The area under curve, AUC0-4 h, for ethiofos (2858 +/- 314 nM h ml-1) was not significantly different from that of 14C (3038 +/- 692 nM h ml-1) or total material convertible to WR-1065 (total WR-1065, 3324 +/- 612 nM h ml-1), indicating a low level of metabolism.",The disposition of ethiofos (WR-2721) in the isolated perfused rat liver. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2537989/),[h·nM] / [ml],2858,189567,DB01143,Amifostine
,2537989,"area under curve, AUC0-4 h","The area under curve, AUC0-4 h, for ethiofos (2858 +/- 314 nM h ml-1) was not significantly different from that of 14C (3038 +/- 692 nM h ml-1) or total material convertible to WR-1065 (total WR-1065, 3324 +/- 612 nM h ml-1), indicating a low level of metabolism.",The disposition of ethiofos (WR-2721) in the isolated perfused rat liver. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2537989/),[h·nM] / [ml],3038,189568,DB01143,Amifostine
,2537989,WR-1065,"The area under curve, AUC0-4 h, for ethiofos (2858 +/- 314 nM h ml-1) was not significantly different from that of 14C (3038 +/- 692 nM h ml-1) or total material convertible to WR-1065 (total WR-1065, 3324 +/- 612 nM h ml-1), indicating a low level of metabolism.",The disposition of ethiofos (WR-2721) in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2537989/),[h·nM] / [ml],3324,189569,DB01143,Amifostine
,2537989,AUC0-4 h,The AUC0-4 h for free WR-1065 (37.5 +/- 23.3 nM h ml-1) was less than 2% of ethiofos.,The disposition of ethiofos (WR-2721) in the isolated perfused rat liver. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2537989/),[h·nM] / [ml],37.5,189570,DB01143,Amifostine
below,2537989,Biliary elimination,"Biliary elimination of ethiofos, WR-1065, and 14C was below 1%.",The disposition of ethiofos (WR-2721) in the isolated perfused rat liver. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2537989/),%,1,189571,DB01143,Amifostine
,29482122,limit of quantification (LOQ),"The method exhibits a limit of quantification (LOQ) of 7.4 nM in plasma, which is a significant improvement over conventional approaches that utilize LC-electrochemical detection (ECD) (LOQ 150 nM or higher).",Evaluation of a method for measuring the radioprotective metabolite WR-1065 in plasma using chemical derivatization combined with UHPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29482122/),nM,7.4,196441,DB01143,Amifostine
,29482122,bioavailability,The bioavailability of WR-1065 was 61.5% after direct jejunal injection indicating rapid conversion and absorption of the metabolite in the intestinal tract.,Evaluation of a method for measuring the radioprotective metabolite WR-1065 in plasma using chemical derivatization combined with UHPLC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29482122/),%,61.5,196442,DB01143,Amifostine
,3019968,plasma clearance,An average plasma clearance value of 2.17 L/min was obtained.,Human pharmacokinetics of WR-2721. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3019968/),[l] / [min],2.17,206706,DB01143,Amifostine
,3019968,steady-state volume of distribution,The mean value of 6.44 L obtained for the steady-state volume of distribution indicates that the extravascular space occupied by the drug is small.,Human pharmacokinetics of WR-2721. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3019968/),l,6.44,206707,DB01143,Amifostine
,12433814,Pulmonary extraction,"Pulmonary extraction of amifostine was low at 7%, whereas renal extraction was intermediate at 57%.","Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433814/),%,7,232306,DB01143,Amifostine
,12433814,blood clearance,"As a result, saturability was observed in the gastrointestinal blood clearance (i.e., from 9.8 to 2.8-3.3 ml/min/kg) and total body plasma clearance of amifostine (i.e., from 52.6 to about 37.3 ml/min/kg), as the doses increased.","Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433814/),[ml] / [kg·min],9.8,232307,DB01143,Amifostine
,12433814,total body plasma clearance,"As a result, saturability was observed in the gastrointestinal blood clearance (i.e., from 9.8 to 2.8-3.3 ml/min/kg) and total body plasma clearance of amifostine (i.e., from 52.6 to about 37.3 ml/min/kg), as the doses increased.","Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433814/),[ml] / [kg·min],52.6 to about 37.3,232308,DB01143,Amifostine
,11550166,elimination half-life,The median elimination half-life of amifostine (9.3 minutes) and WR-1065 (15 minutes) was much shorter than the disulfide metabolites (74.4 minutes).,"Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550166/),min,9.3,235654,DB01143,Amifostine
,11550166,elimination half-life,The median elimination half-life of amifostine (9.3 minutes) and WR-1065 (15 minutes) was much shorter than the disulfide metabolites (74.4 minutes).,"Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550166/),min,15,235655,DB01143,Amifostine
,11550166,elimination half-life,The median elimination half-life of amifostine (9.3 minutes) and WR-1065 (15 minutes) was much shorter than the disulfide metabolites (74.4 minutes).,"Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550166/),min,74.4,235656,DB01143,Amifostine
,12065057,LD50/30,"LD50/30 was 7.97, 8.74 and 16.64 Gy for the control, three-placebo pellet (dose reduction factor, DRF=1.10, p<0.01), and three-amifostine pellet (DRF=1.79, p<0.01) groups respectively in mouse exposed to radiation 2h after implantation.","Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065057/),gy,7.97,265549,DB01143,Amifostine
,12065057,LD50/30,"LD50/30 was 7.97, 8.74 and 16.64 Gy for the control, three-placebo pellet (dose reduction factor, DRF=1.10, p<0.01), and three-amifostine pellet (DRF=1.79, p<0.01) groups respectively in mouse exposed to radiation 2h after implantation.","Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065057/),gy,8.74,265550,DB01143,Amifostine
,12065057,LD50/30,"LD50/30 was 7.97, 8.74 and 16.64 Gy for the control, three-placebo pellet (dose reduction factor, DRF=1.10, p<0.01), and three-amifostine pellet (DRF=1.79, p<0.01) groups respectively in mouse exposed to radiation 2h after implantation.","Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065057/),gy,16.64,265551,DB01143,Amifostine
